GreenLight Biosciences Profit Margin

The latest profit margin for GRNA is -1549.12% as of March 2023. That compares with -12584.61% in the prior-year period — up 87.7% year over year. That is below the sector sector average of 21.34%. Investors often review this figure alongside GreenLight Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, GRNA's profit margin moved from -12584.61% to -1549.12% — a 87.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GreenLight Biosciences's valuation or profitability profile.

Against its sector companies, GRNA currently prints -1549.12% for profit margin, while the sector average sits near 21.34%. That is roughly 7358.6% below the sector mean. Large gaps often invite a closer look at GreenLight Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively GreenLight Biosciences converts resources into returns. At -1549.12%, GRNA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -12584.61% in the prior-year period — up 87.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GRNA's profit margin (-1549.12%), review year-over-year change from -12584.61%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.